OR
Cardiology - Vascular Medicine
COBRRA 2026 provides head-to-head randomized evidence comparing apixaban with rivaroxaban in 2,760 patients with acute symptomatic PE or proximal DVT. Over 3 months, clinically relevant bleeding occurred less frequently with apixaban than rivaroxaban (3.3% vs 7.1%; RR 0.46; 95% CI, 0.33–0.65). This update explores the implications for initial VTE treatment, the 2026 ACC Scientific Statement, and individualized decisions regarding extended anticoagulation based on recurrent VTE and bleeding risks.
0 Likes
0 Comments
Every decision in antithrombotic therapy carries a delicate balance between preventing thrombosis and minimizing bleeding risk. Join Clot Chronicles, a dedicated forum where healthcare professionals can engage in scientific discussions, gain practical clinical insights, and strengthen evidence-based decision-making to improve patient outcomes.
© 2026 i-rhythm, All Rights Reserved. MSN i-Rhythm does not provide medical advice, diagnosis or treatment.
For unrestricted access to content and a seamless experience,
Complete your profile to help us deliver a more personalized experience.